CN1757390A - Obtundent-Tilidin hydrochloride preparation - Google Patents
Obtundent-Tilidin hydrochloride preparation Download PDFInfo
- Publication number
- CN1757390A CN1757390A CN 200510012547 CN200510012547A CN1757390A CN 1757390 A CN1757390 A CN 1757390A CN 200510012547 CN200510012547 CN 200510012547 CN 200510012547 A CN200510012547 A CN 200510012547A CN 1757390 A CN1757390 A CN 1757390A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tilidine
- agent
- tilidine hydrochloride
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 6
- MUWDJVKYGSDUSH-KALLACGZSA-N ethyl (1s,2r)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C MUWDJVKYGSDUSH-KALLACGZSA-N 0.000 claims abstract description 19
- 229960001502 tilidine hydrochloride Drugs 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 229960001402 tilidine Drugs 0.000 claims description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004756 ethanol Drugs 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- -1 tilidine hydrochlorides Chemical class 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 239000007779 soft material Substances 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 6
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 206010012335 Dependence Diseases 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- VRAIHTAYLFXSJJ-UHFFFAOYSA-N alumane Chemical compound [AlH3].[AlH3] VRAIHTAYLFXSJJ-UHFFFAOYSA-N 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229950005770 hyprolose Drugs 0.000 description 3
- PDJZPNKVLDWEKI-GOEBONIOSA-N (1R,2S)-nortilidine Chemical compound C=1C=CC=CC=1[C@]1(C(=O)OCC)CCC=C[C@@H]1NC PDJZPNKVLDWEKI-GOEBONIOSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229920003020 cross-linked polyethylene Polymers 0.000 description 2
- 239000004703 cross-linked polyethylene Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000222712 Kinetoplastida Species 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- SCGJLFGXXZTXSX-UHFFFAOYSA-N copper;ethanol Chemical compound [Cu].CCO SCGJLFGXXZTXSX-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
An analgesic in the form of tablet or capsule is prepared from tilidine hydrochloride, filler, disintegrant, lubricant and adhesive.
Description
Technical field
The present invention relates to analgesic formulations, particularly is a kind of preparation of obtundent-Tilidin hydrochloride.
Background technology
Tilidine hydrochloride is a complete synthesis opium analgesic, acts on the central nervous system, can suppress pain sensation maincenter by selectivity, other sensation is not had influence, and keep patient's Consciousness, belong to the narcosis analgesic thing, have dependency, be used for the pain relieving of moderate to severe pain.Tilidine hydrochloride is a kind of prodrug, and itself does not have analgesic effect, almost completely is being converted into μ-receptor stimulating agent Nortilidine through behind the liver first-pass effect.Having spinal cord produces analgesia, suppresses to breathe, make effects such as the people is glad, physical dependence with the upper part.Tilidate has advantages such as dosage is low, and analgesic effect is good, and addiction is little.Its analgesic activity mechanism is a kind of opioid receptor agonist for the catabolite Nortilidine of tilidate, and with the effect of receptors bind simulation endogenous analgesic opioid peptide, the interior anti-pain sensation of kinetoplast system realizes.Have spasmolysis simultaneously, unlike common opioid analgesics (as morphine etc.), can not produce respiration inhibition effect and obstipation, addiction is low.Its analgesic activity intensity is not subjected to the influence of administering mode, onset in 5-20 minute after the administration, and the persistent period is about 5-6 hour, is WHO " three step analgesia guidelines " recommended drug, and its structural formula is as follows:
It is low that tilidate has a dosage, good analgesic effect, the advantage that addiction is little.For further reducing addiction, Germany has developed the compound preparation of tilidate and Na Luoxi paulownia.But tilidate is urgently soluble in water.Have and intensively draw moistly,, can decomposite impurity such as methyl tilidate, nor-tilidate the photo-thermal instability.Affect the treatment and clinical use.
Summary of the invention
For promoting the clinical practice of tilidate, give full play to its curative effect, satisfy the demand of clinical ground analgesic.The invention provides tilidine hydrochloride tablet and hard capsule.Tilidine hydrochloride tablet of the present invention or hard capsule are made by following weight proportion by the host and the adjuvant of following weight proportion;
A, tilidine hydrochloride 4-8
B, filler 4-12
C, disintegrating agent 2-10
D, lubricant 0.04-1
E, wetting agent or binding agent 1-6.
The preferred weight proportioning of raw material is:
A, tilidine hydrochloride 5-7
B, filler 5-11
C, disintegrating agent 4-8
D, lubricant 0.06-0.08
E, wetting agent or binding agent 2-5.
Its filler can be pregelatinized Starch, lactose, Macrogol 4000, polyethylene glycol 6000, mannitol, a kind of or two kinds or the two or more mixture of xylitol.Its disintegrating agent can be that basic Starch Sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, crosslinked polyethylene are given a tongue-lashing and coughed up one of bright, the crosslinked first of alkane shallow lake carboxymethylstach sodium or two kinds or two or more mixture.Its lubricant can be a magnesium stearate, or Pulvis Talci or micropowder silica gel, or magnesium stearate and talcous mixture.Its wetting agent is ethanol or dehydrated alcohol.Its binding agent is one of starch slurry, polyvidone, cellulose family, or the mixture of two or more material.
Its manufacture method is: filler, disintegrating agent, lubricant are sieved, with the tilidine hydrochloride of recipe quantity and filler, interior disintegrating agent mix homogeneously, add wetting agent again and make soft material, granulation, drying, granulate sieve, add outer disintegrating agent, mix lubricant is even, tabletting or filling after the assay was approved, tablet check back bag film-coat, promptly aluminum-plastic packaged.The present invention selects for use dehydrated alcohol etc. to make wetting agent, and adopts 45 ℃ of-50 ℃ of dryings of low temperature; Select for use do not have draw moist, can improve tablet appearance, release fast, assay is not had influence, flowability, good filler lactose that compressibility is strong etc.; Select for use the hypromellose with good disintegrative, compressibility, the low hyprolose of getting to make interior disintegrating agent (filler), can quicken the medicine stripping; Select for use have good flowability, compressibility, can improve the tablet molding, increase tablet hardness, carboxymethyl starch sodium that disintegrating property is good etc. makes outer disintegrating agent, can promote principal agent disintegrate stripping from preparation; Select for use have good tack and with the granule mixing after be evenly distributed and not easily separated, only with showing on a small quantity well.Lubrication makes the bright and clean magnesium stearate attractive in appearance of tablet face make lubricant.Thereby make tablet of the present invention unilateral complete, bright and clean, color and luster is even, in water rapidly disintegrate stripping and methyl tilidate etc. to decompose the impurity that produces few, draw moist very lowly, biological utilisation is very high, and is easy to use, can guarantee curative effect, addiction is very little.
The specific embodiment
Embodiment 1:
Take by weighing tilidine hydrochloride 40 grams, add pregelatinized Starch 35 grams, microcrystalline Cellulose 15 grams, low hyprolose 20 grams of getting, polyethylene glycol 6000 40 gram mix homogeneously, add 15% starch slurry and make soft material, soft material is granulated 50 ℃ of dryings, dried granule through 14 mesh sieve granulate by 14 mesh sieves, adds crosslinked carboxymethyl fecula 5 grams, magnesium stearate 5 gram mix homogeneously, after the assay was approved tabletting or be filled in the hard capsule.Use LE coating materials bag film-coat after the assay was approved, plastic-aluminum (aluminum inscription) packing, outer package is promptly.
Embodiment 2
Take by weighing tilidine hydrochloride 30 gram, add mannitol 30 grams,, microcrystalline Cellulose 35 grams.Crosslinked polyethylene is given a tongue-lashing pyrrolidone 10 grams, Macrogol 4000 state 15 gram mix homogeneously, add 5% polyvidone ethanol solution 5 and restrain into suitable soft material, soft material is granulated by 14 mesh sieves, 50 ℃ of dryings, dried granule are through 14 mesh sieve granulate, add crosslinked carboxymethylstach sodium 5 gram Pulvis Talci 3 grams, magnesium stearate 2 gram mix homogeneously, tabletting or fillings after the assay was approved, tablet is used LE coating materials bag film-coat after the assay was approved, and plastic-aluminum (aluminum aluminum) packing, outer package are promptly.
Embodiment 3
Take by weighing tilidine hydrochloride 30 grams. Add xylitol 20 grams, carboxymethyl starch sodium 20 grams.Crospolyvinylpyrrolidone 40 grams.Polyethylene glycol 6000 40 gram mix homogeneously, add 3% poly-dimension copper ethanol solution 30 and restrain into suitable soft material, soft material is granulated by 14 mesh sieves, 50 ℃ of dryings, dried granule are through 14 mesh sieve granulate, add carboxymethyl starch sodium 5 grams, Pulvis Talci 3 grams, mix homogeneously, be up to the standards tabletting or filling, tablet is used LE coating film clothing after the assay was approved, plastic-aluminum (aluminum aluminum) packing, outer package promptly.
Embodiment 4
Take by weighing hydrochloric acid for fixed 30 grams of agent, add lactose 40 grams, carboxymethyl starch sodium 21 grams, crosslinked carboxymethylstach sodium 16 grams, Macrogol 4000 30 gram mix homogeneously.Add ethanol 10 and restrain into suitable soft material, soft material adds carboxymethyl starch sodium 5 grams by 14 mesh sieve granulate, magnesium stearate 5 gram mix homogeneously, tabletting or filling after the assay was approved, tablet is after the assay was approved, with LE coating materials bag film-coat, plastic-aluminum (aluminum aluminum) packing, outer package is promptly.
Embodiment 5
Take by weighing tilidine hydrochloride 40 grams, add lactose 40 grams, hypromellose 18 grams, low hyprolose 18 grams, the Macrogol 4000 25 gram mix homogeneously got, add dehydrated alcohol 15 and restrain into suitable soft material, soft material is upright by 14 mesh sieve systems, 45 ℃ of dryings, dried granule are through 14 mesh sieve granulate, add carboxymethyl starch sodium 5 grams, micropowder silica gel 5 gram mix homogeneously, LE coating materials bag film-coat is used in tabletting or filling after the assay was approved, pateat universis per praesentes after the assay was approved, and plastic-aluminum (aluminum aluminum) packing, outer package are promptly.
Claims (7)
1, a kind of preparation of obtundent-Tilidin hydrochloride is characterized in that it being tablet or hard capsule, is made by following materials of weight proportions:
A, tilidine hydrochloride 4-8
B, filler 4-12
C, disintegrating agent 2-10
D, lubricant 0.04-1
E, wetting agent or binding agent 1-6.
2, the preparation of tilidine hydrochloride according to claim 1 is characterized in that wherein the weight ratio of each raw material is:
A, tilidine hydrochloride 5-7
B, filler 5-11
C, disintegrating agent 4-8
D, lubricant 0.06-0.08
E, wetting agent or binding agent 2-5.
3, the preparation of tilidine hydrochloride according to claim 1 and 2 is characterized in that said filler is a kind of of pregelatinized Starch lactose, Macrogol 4000, polyethylene glycol 6000, mannitol or xylitol, or two kinds, or two or more mixture.
4, the preparation of tilidine hydrochloride according to claim 3, it is characterized in that said disintegrating agent is a kind of of carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, crospolyvinylpyrrolidone, crosslinked carboxymethylstach sodium, or two or more mixture.
5, the preparation of tilidine hydrochloride according to claim 4 is characterized in that said lubricant is magnesium stearate or Pulvis Talci, or micropowder silica gel, or magnesium stearate and talcous mixture.
6, the preparation of tilidine hydrochloride according to claim 5 is characterized in that said wetting agent is ethanol or dehydrated alcohol.
7, according to the preparation of claims 6 described tilidine hydrochlorides, it is characterized in that said binding agent is a starch slurry, or polyvidone, or cellulose family.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510012547 CN1757390A (en) | 2005-05-30 | 2005-05-30 | Obtundent-Tilidin hydrochloride preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510012547 CN1757390A (en) | 2005-05-30 | 2005-05-30 | Obtundent-Tilidin hydrochloride preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1757390A true CN1757390A (en) | 2006-04-12 |
Family
ID=36703058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510012547 Pending CN1757390A (en) | 2005-05-30 | 2005-05-30 | Obtundent-Tilidin hydrochloride preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1757390A (en) |
-
2005
- 2005-05-30 CN CN 200510012547 patent/CN1757390A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI234459B (en) | Eplerenone compositions | |
| CN104666238B (en) | 3 hydroxyl fourth of stability-enhanced (Z) 2 cyano group 2 olefin(e) acid (4 ' trifluoromethyl) acid amides tablet formulation | |
| KR100202154B1 (en) | Film coated tablets containing paracetamol and domperidone | |
| CN102858324A (en) | Double-layer pharmaceutical formulations containing opioid agonists and antagonists | |
| SK10012001A3 (en) | Medicinal formulations containing an opioid and an alpha-antagonist | |
| RO118563B1 (en) | Dosed oral composition with instantaneous decomposition, and process for obtaining the same | |
| WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
| KR20120117985A (en) | Dry-coated orally disintegrating tablet | |
| CN104814923A (en) | Tamsulosin Hydrochloride sustained-release preparation, preparation method and applications thereof | |
| JP2013533881A (en) | Pharmaceutical composition containing vanoxerin | |
| CN101732312A (en) | Huperzine A oral formulation and a preparation method thereof | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN102088972A (en) | Pharmaceutical compositions containing imidazole-5-carboxylic acid derivatives and preparation method and use thereof | |
| JP2847866B2 (en) | Peptic ulcer treatment | |
| CN1757390A (en) | Obtundent-Tilidin hydrochloride preparation | |
| WO2004002475A1 (en) | Sustained release tablet containing indapamide | |
| CN100471497C (en) | Naloxone Hydrochloride nose powder preparation | |
| CN101912373A (en) | Stable cefeclor dispersible tablet and preparation method thereof | |
| CN1709255A (en) | Antipyetics hydrogen chloride tilidine compound formulation | |
| EP3911305B1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| EP3880171B1 (en) | Ibuprofen-containing oral pharmaceutical formulation | |
| CN101756977A (en) | Slow-release preparation of azelnidipine and preparation method thereof | |
| CN1546029A (en) | Gatifloxacin dispersible tablet and its preparation process | |
| CN1557309A (en) | Amlodipine dispersion tablet and its preparation method | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |